Clinicopathologic characteristics, survival, and treatments for gastric adenosquamous carcinoma: a population-based study

Current Oncology

View Publication Info
 
 
Field Value
 
Title Clinicopathologic characteristics, survival, and treatments for gastric adenosquamous carcinoma: a population-based study
 
Creator Li, H.S.
Zhang, M.Y.
Cheng, K.
Chen, Y.
Zhou, Y.W.
Liu, J.Y.
 
Subject Adenosquamous carcinoma
stomach
disease characteristics
survival
treatments
 
Description Background Gastric adenosquamous carcinoma (gasc) is a rare entity with distinctive characteristics that are not fully understood. In the present study, we evaluated the characteristics of this rare disease.
Methods The U.S. Surveillance, Epidemiology, and End Results program database was searched to determine the clinicopathologic features, prognostic factors, and treatments for 246 patients with gasc and 42,735 patients with gastric adenocarcinoma (gac).
Results Relative to gac, gasc is associated with higher proportions of cardia involvement, high-grade tumours, deep tumour invasion, metastatic lymph nodes, and chemotherapy treatment. In patients who underwent potentially curative surgery (pcs), gasc was associated with a higher proportion of radiotherapy use and poorer overall survival (p < 0.001), although no significant difference (p = 0.802) was observed after propensity score matching (psm). Multi­variate analysis after psm revealed that the independent prognostic factors for gasc were TNM stage [hazard ratio (hr): 1.512; p = 0.021] and regional nodes examined (hr: 0.588; p = 0.02). In patients with advanced disease, no significant difference in survival between gasc and gac was observed (p = 0.212), although survival was significantly poorer for gasc after psm (p = 0.019). Multivariate analysis after psm revealed that the independent prognostic factors for gasc were invasion depth (hr: 1.303; p = 0.036) and chemotherapy (hr: 0.444; p < 0.001).
Conclusions Relative to gac, gasc was associated with more aggressive features, although survival outcomes were similar after pcs. Chemotherapy remains a mainstay of treatment for patients with advanced gasc, but its role remains unclear for patients who are undergoing pcs.
 
Publisher Multimed Inc.
 
Date 2020-08-07
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/6337
10.3747/co.27.6337
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/6337/9625
http://www.current-oncology.com/index.php/oncology/article/view/6337/9533
http://www.current-oncology.com/index.php/oncology/article/view/6337/9689
 
Rights Copyright (c) 2020 Current Oncology
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library